ZNTL — Zentalis Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $101.15m
- -$179.55m
- $67.43m
- 32
- 45
- 55
- 40
Annual cashflow statement for Zentalis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -119 | -166 | -237 | -292 | -166 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 23.7 | -5.1 | 59.5 | 78.1 | 10.3 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 7.84 | 16.6 | 13.3 | 5.86 | -16.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -86.8 | -154 | -164 | -208 | -171 |
| Capital Expenditures | -0.758 | -6.11 | -2.55 | -0.583 | -0.221 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -284 | -12 | -112 | -43.9 | 177 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -285 | -18.1 | -114 | -44.5 | 177 |
| Financing Cash Flow Items | 18.4 | -1.15 | 0 | 0 | -0.241 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 360 | 179 | 261 | 237 | 0.108 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.2 | 6.31 | -16.9 | -15 | 5.81 |